Journal: bioRxiv
Article Title: Dopamine transporter threonine-53 phosphorylation dictates kappa opioid receptor mediated locomotor suppression and conditioned place aversion via transporter upregulation
doi: 10.1101/2024.05.09.593368
Figure Lengend Snippet: Drug administrations and synaptosome preparations are given under the materials and methods section. Using indicated specific antibodies, total and surface expression of pT53-DAT, DAT and calnexin were visualized and quantified following surface protein biotinylation. Representative immunoblots from three independent experiments show changes in (A) total and (B) surface (biotinylated) pT53-DAT (∼60-55kDa), DAT (∼65 kDa) and calnexin (∼90 kDa) in the ventral and dorsal striatum of WT and DAT-Ala53 mice. The specificities of DAT and pT53-DAT immunoreactive bands by the antibodies used were established in our previous publication . Bar graph shows quantified arbitrary band densities of total pT53-DAT (C), DAT (E) and biotinylated surface pT53-DAT (D), and DAT (F). Each data point represents an individual mouse, and the data presented as Mean ± SEM. WT (n = 3) and DAT-Ala53 (n = 3) mice. Compared with vehicle control, U69593 increased total and surface pT53-DAT levels and surface DAT expression without altering the total expression of DAT and calnexin in the ventral and dorsal striatum of WT but not DAT-Ala53 mice. * P = 0.05, ** P < 0.01, ^^ P < 0.01, ^^^ P < 0.001, ns: nonsignificant. Comparisons between specific pairs are indicated in the figures. Data were analyzed by two-way ANOVA with Bonferroni’s multiple comparisons.
Article Snippet: Total levels of DAT and pT53-DAT were determined using primary antibodies for DAT (mouse anti-dopamine transporter monoclonal, clone mAb16, Cat. No: MABN669, 1:2000 dilution, MilliporeSigma, Burlington, MA) and pT53-DAT (rabbit anti-phospho-Thr53 dopamine transporter polyclonal, Cat. No: p435-53, 1:2000 dilution, PhosphoSolutions Inc., Aurora, CO) respectively.
Techniques: Expressing, Western Blot, Control